vs
LEXICON PHARMACEUTICALS, INC.（LXRX）与Rithm Property Trust Inc.（RPT）财务数据对比。点击上方公司名可切换其他公司
LEXICON PHARMACEUTICALS, INC.的季度营收约是Rithm Property Trust Inc.的1.6倍（$5.5M vs $3.4M），Rithm Property Trust Inc.净利率更高（95.4% vs -282.7%，领先378.1%），LEXICON PHARMACEUTICALS, INC.同比增速更快（254.4% vs -39.7%），过去两年LEXICON PHARMACEUTICALS, INC.的营收复合增速更高（124.2% vs -43.2%）
Lexicon制药是一家成立于1995年的生物制药企业，总部位于美国得克萨斯州伍德兰兹，最初名为Lexicon Genetics，专注于开发人类疾病治疗药物。公司凭借专利小鼠基因敲除技术与强大的体内筛选能力，在Genome5000项目中完成了近5000个基因的研究，筛选出大量候选药物靶点。
Rithm Property Trust Inc.旗下的里思资本是一家总部位于纽约的美国投资管理公司，核心业务聚焦于房地产投资及另类投资领域，是该赛道颇具影响力的专业投资机构。
LXRX vs RPT — 直观对比
营收规模更大
LXRX
是对方的1.6倍
$3.4M
营收增速更快
LXRX
高出294.1%
-39.7%
净利率更高
RPT
高出378.1%
-282.7%
两年增速更快
LXRX
近两年复合增速
-43.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.5M | $3.4M |
| 净利润 | $-15.5M | $3.2M |
| 毛利率 | 96.3% | — |
| 营业利润率 | -269.1% | 99.6% |
| 净利率 | -282.7% | 95.4% |
| 营收同比 | 254.4% | -39.7% |
| 净利润同比 | 54.0% | 11.2% |
| 每股收益（稀释后） | $-0.04 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LXRXRPT
| Q4 25 | $5.5M | $3.4M | ||
| Q3 25 | $14.2M | $4.0M | ||
| Q2 25 | $28.9M | $4.2M | ||
| Q1 25 | $1.3M | $249.0K | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $1.6M | — | ||
| Q1 24 | $1.1M | — |
净利润LXRXRPT
| Q4 25 | $-15.5M | $3.2M | ||
| Q3 25 | $-12.8M | $-273.0K | ||
| Q2 25 | $3.3M | $1.9M | ||
| Q1 25 | $-25.3M | $-3.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-64.8M | — | ||
| Q2 24 | $-53.4M | — | ||
| Q1 24 | $-48.4M | — |
毛利率LXRXRPT
| Q4 25 | 96.3% | — | ||
| Q3 25 | 99.9% | — | ||
| Q2 25 | 99.9% | — | ||
| Q1 25 | 97.6% | — | ||
| Q4 24 | 77.5% | — | ||
| Q3 24 | 95.9% | — | ||
| Q2 24 | 89.7% | — | ||
| Q1 24 | 97.2% | — |
营业利润率LXRXRPT
| Q4 25 | -269.1% | 99.6% | ||
| Q3 25 | -85.9% | -6.2% | ||
| Q2 25 | 12.9% | 45.7% | ||
| Q1 25 | -2034.8% | -1416.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -3658.4% | — | ||
| Q2 24 | -3423.3% | — | ||
| Q1 24 | -4147.6% | — |
净利率LXRXRPT
| Q4 25 | -282.7% | 95.4% | ||
| Q3 25 | -90.0% | -6.8% | ||
| Q2 25 | 11.3% | 45.1% | ||
| Q1 25 | -2004.4% | -1363.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -3722.6% | — | ||
| Q2 24 | -3304.2% | — | ||
| Q1 24 | -4427.9% | — |
每股收益（稀释后）LXRXRPT
| Q4 25 | $-0.04 | $-0.26 | ||
| Q3 25 | $-0.04 | $-0.03 | ||
| Q2 25 | $0.01 | $0.01 | ||
| Q1 25 | $-0.07 | $-0.08 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.18 | — | ||
| Q2 24 | $-0.17 | — | ||
| Q1 24 | $-0.20 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $96.2M | $79.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $107.5M | $291.6M |
| 总资产 | $185.0M | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LXRXRPT
| Q4 25 | $96.2M | $79.3M | ||
| Q3 25 | $116.0M | $81.4M | ||
| Q2 25 | $139.0M | $98.6M | ||
| Q1 25 | $194.8M | $97.4M | ||
| Q4 24 | $238.0M | — | ||
| Q3 24 | $258.4M | — | ||
| Q2 24 | $310.0M | — | ||
| Q1 24 | $355.6M | — |
股东权益LXRXRPT
| Q4 25 | $107.5M | $291.6M | ||
| Q3 25 | $120.2M | $291.7M | ||
| Q2 25 | $129.4M | $294.7M | ||
| Q1 25 | $123.0M | $296.1M | ||
| Q4 24 | $145.9M | — | ||
| Q3 24 | $178.5M | — | ||
| Q2 24 | $240.0M | — | ||
| Q1 24 | $288.9M | — |
总资产LXRXRPT
| Q4 25 | $185.0M | $1.0B | ||
| Q3 25 | $205.9M | $1.0B | ||
| Q2 25 | $225.6M | $1.0B | ||
| Q1 25 | $297.7M | $1.0B | ||
| Q4 24 | $298.4M | — | ||
| Q3 24 | $321.1M | — | ||
| Q2 24 | $373.4M | — | ||
| Q1 24 | $417.2M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-17.2M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | -2.56× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流LXRXRPT
| Q4 25 | $-17.2M | $-8.3M | ||
| Q3 25 | $-23.8M | $-5.8M | ||
| Q2 25 | $17.0M | $-25.0K | ||
| Q1 25 | $-43.8M | $-1.6M | ||
| Q4 24 | $-178.8M | — | ||
| Q3 24 | $-53.6M | — | ||
| Q2 24 | $-48.5M | — | ||
| Q1 24 | $-55.1M | — |
自由现金流LXRXRPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-179.8M | — | ||
| Q3 24 | $-53.9M | — | ||
| Q2 24 | $-48.8M | — | ||
| Q1 24 | — | — |
自由现金流率LXRXRPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -11600.7% | — | ||
| Q3 24 | -3097.4% | — | ||
| Q2 24 | -3017.3% | — | ||
| Q1 24 | — | — |
资本支出强度LXRXRPT
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 66.5% | — | ||
| Q3 24 | 17.6% | — | ||
| Q2 24 | 15.5% | — | ||
| Q1 24 | 0.0% | — |
现金转化率LXRXRPT
| Q4 25 | — | -2.56× | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.23× | -0.01× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
